drugset / Trial / NCT01074463

Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions

NCT01074463

Phase 1 Completed 24 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-label

Summary

The object of this study was to compare the relative bioavailability (rate and extent of absorption) of Pramipexole Dihydrochloride Tablets 0.25 mg by Barr Laboratories, Inc. with that of Mirapex® Tablets 0.25 mg distributed by Boehringer Ingelheim Pharmaceuticals, Inc. following a single oral dose in healthy adults under non-fasting conditions.

Timeline

Start
2005-02
Primary completion
2005-03
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pramipexole Unknown 0.25 mg Oral

Indications

No indication recorded.